Belite Bio, Inc expected to post a loss of 79 cents a share - Earnings Preview

Belite Bio

11/08/2026 14:33

Belite Bio, Inc BLTE.OQ BLTE.O is expected to  show no change in quarterly revenue when it reports  results on August 13 for the period ending June 30 2026

​LSEG's mean analyst estimate for Belite Bio, Inc is for a loss of 79 cents per share. 
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."  
The mean earnings estimate of analysts was unchanged in the last three months. ​
Wall Street's median 12-month price target for Belite Bio, Inc is $200.50, about 19.9% above its last closing price of $167.26
Previous quarterly performance (using preferred earnings measure in US dollars). ​
QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE 
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2026
-0.69
-0.64
-0.68
Missed
-7
Dec. 31 2026
-0.54
-0.55
-0.70
Missed
-28.1
Sep. 30 2025
-0.47
-0.49
-0.65
Missed
-33.3​
Jun. 30 2025
-0.47
-0.42
-0.50
Missed
-19.8
​​Mar. 31 2025
-0.34
-0.37
-0.45
Missed
-20.5
Dec. 31 2024
-0.29
-0.31
-0.32
Missed
-4​
Sep. 30 2024
-0.29
-0.29
-0.28
Beat
2.8
Jun. 30 2024
-0.27
-0.25
-0.31
Missed
-22.7
This summary was machine generated August 11 at 13:33 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)